Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development

Melissa A. Tran,1 Charles D. Smith,6 Mark Kester,1,4 and Gavin P. Robertson1,2,3,4,5

Abstract

Purpose: Deregulation of phosphatidylinositol 3-kinase/Akt and Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathways occurs in melanoma and breast cancer, deregulating normal cellular apoptosis and proliferation. Therapeutic cocktails simultaneously targeting these pathways could promote synergistically acting tumor inhibition. However, agents with manageable toxicity and mechanistic basis for synergy need identification. The purpose of this study is to evaluate the preclinical therapeutic efficacy and associated toxicity of combining sorafenib with nanoliposomal ceramide.

Experimental Design: Effects of sorafenib and nanoliposomal ceramide as single and combinatorial agents were examined on cultured cells using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt assays and CalcuSyn software used to assess synergistic or additive inhibition. Western blotting measured cooperative effects on signaling pathways. Rates of proliferation, apoptosis, and angiogenesis were measured in size- and time-matched tumors to identify mechanistic basis for inhibition. Toxicity was evaluated measuring animal weight, blood toxicity parameters, and changes in liver histology.

Results: Sorafenib and nanoliposomal ceramide synergistically inhibited cultured cells by cooperatively targeting mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling. A 1- to 2-fold increase in cellular apoptosis and 3- to 4-fold decrease in cellular proliferation were observed following combination treatment compared with single agents, which caused synergistically acting inhibition. In vivo, an ~30% increase in tumor inhibition compared with sorafenib treatment alone and an ~58% reduction in tumor size compared with nanoliposomal ceramide monotherapy occurred by doubling apoptosis rates with negligible systemic toxicity.

Conclusions: This study shows that nanoliposomal ceramide enhances effectiveness of sorafenib causing synergistic inhibition. Thus, a foundation is established for clinical trials evaluating the efficacy of combining sorafenib with nanoliposomal ceramide for treatment of cancers.

Although novel cancer therapies are continually being developed, a cure has remained elusive for many advanced-stage solid tumor cancers. This has led to investigation of strategies simultaneously inhibiting the action of multiple targets or pathways to regulate processes promoting tumor development. These include concurrently targeting proteins or pathways regulating apoptotic resistance, proliferation, angiogenesis, cellular proliferation, tissue invasion, or metastasis (1). However, success requires identification of agents that, when combined, lead to synergistic tumor inhibition without significant systemic toxicity.

Both melanoma and breast cancer have deregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt and Ras/Raf/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathways, which regulate apoptosis and cellular proliferation, respectively (2, 3). Thus, a cocktail of agents targeting these pathways could have significant therapeutic potential by simultaneously increasing cellular apoptosis and/or decreasing proliferation in a cooperative manner. However, agents synergistically targeting these pathways with minimal associated toxicity need to be identified and the underlying mechanistic basis for synergy validated in preclinical animal models.

The MAPK signaling cascade relays an ordered series of consecutive phosphorylation events from cell surface, via Ras, Raf, MEK, and ERK, to nucleus (4, 5). In ~60% of melanomas, activation occurs through mutation of B-Raf (T1799A), an intermediate protein in the signaling pathway, resulting in...
kinase activity 10.7 times higher than occurs in normal cells (6–9). The MAPK pathway is similarly activated in breast cancer cells with ~100% having pathway activation due in part to aberrant Ras or Raf-1 activity (10). In melanoma and breast cancer animal models, inhibition of the MAPK signaling cascade significantly retards tumorigenesis, making targeting this pathway an important component of a combinatorial therapeutic approach (11–14).

The MAPK signaling cascade has been inhibited in both melanomas and breast cancer preclinical models using sorafenib (BAY 43-9006), which is a nonspecific Raf kinase inhibitor (14, 15). In animal models, sorafenib effectively reduces melanoma, breast cancer, colon, and lung cancer development (11, 14). However, clinical efficacy has been shown for only renal cell carcinoma, where it is approved for clinical use (16, 17). To improve efficacy for other cancers, novel agent combinations are being evaluated in which sorafenib is combined with agents to identify therapeutic cocktails that simultaneously inhibit pathways resulting in synergy and greater tumor-inhibitory efficacy.

A second pathway deregulated in a large proportion of melanoma and breast cancer is the PI3K/Akt signaling cascade. This pathway relays signals through an ordered series of consecutive phosphorylation events from cell surface, via PI3K and Akt, to a wide range of downstream targets, some of which regulate cellular apoptosis (FOXO, GSK-3, BAD, PRAS40, and MDM2; refs. 18, 19). Deregulation of the apoptotic pathway promotes chemoresistance, reducing the effectiveness of chemotherapeutic agents (1, 20). The PI3K/Akt pathway is activated in ~70% of melanomas and in 25% to 55% of breast cancers (3, 21). In melanoma and breast cancer animal models, inhibition of PI3K/Akt signaling retards tumorigenesis by restoring the apoptotic sensitivity of cancer cells to environmental stimuli and chemotherapeutic agents triggering apoptosis, making targeting this pathway an important component of a combinatorial therapeutic approach (11–13, 21–23).

Although inhibitors of the PI3K/Akt pathway, such as API-2 and rapamycin, have been developed and had varying clinical efficacy, potentially more effective agents with less toxicity are being developed (24). The use of ceramide to inhibit Akt signaling is a novel approach under preclinical evaluation.7 Ceramide targets the PI3K/Akt pathway through dephosphorylation of Akt, leading to increased tumor cell apoptosis and in combination with other chemotherapeutics can enhance cancer cell death (22, 23, 25–31). An obstacle that has limited clinical use of ceramide is its hydrophobicity, which has been overcome by packaging it into a nanoliposomal formulation for systemic delivery (22, 23, 29, 30). Nanoliposomal ceramide can reduce melanoma and breast cancer development by targeting PI3K/Akt signaling (22, 23, 29, 30, 32). It is possible that nanoliposomal ceramide could be combined with other drugs into a therapeutic cocktail that simultaneously inhibits multiple pathways leading to synergistic tumor inhibition. In this study, combining sorafenib and nanoliposomal ceramide has been found to more effectively inhibit melanoma and breast tumor development than either agent alone. By therapeutically targeting the MAPK and PI3K/Akt pathways, these agents cause a 1- to 2-fold increase in cellular apoptosis and 3- to 4-fold decrease in proliferation compared with single agents. An ~30% reduction in tumor development compared with sorafenib alone and ~58% decrease in tumor size compared with nanoliposomal ceramide monotherapy were observed with the combination treatment. Thus, these results lay the groundwork for clinical trials testing the safety and efficacy of combining sorafenib with nanoliposomal ceramide for more effectively treating melanoma and breast cancer patients.

Materials and Methods

Cytotoxicity of sorafenib and nanoliposomal ceramide in cultured cells. Sorafenib [BAY 43-9006; N-(3-trifluoromethyl-4-chlorophenyl)-N’-(4-[2-methylcarbamoyl pyridin-4-yl]oxyphenyl)urea] was prepared as described previously (11). Cytotoxicity of sorafenib and nanoliposomal ceramide alone in fibroblast, breast cancer, and melanoma cells was measured by plating 5 × 10^4 cells into 96-well plates followed by growth for 48 h in a humidified 37°C cell culture incubator. Next, cells were treated with sorafenib, DMSO, nanoliposomal ceramide, or ghost liposomes for 24 h in 2.5% serum medium (sorafenib: 0.5, 1.0, 1.5, and 2.0 μmol/L; nanoliposomal ceramide: 3.125, 6.25, 12.5, and 25 μmol/L). For combination agent studies, 5 × 10^4 cells were plated in 96-well plates, allowed to recover for 48 h, and treated with ghost liposome + DMSO, ghost liposome + sorafenib, nanoliposomal ceramide + DMSO, or nanoliposomal ceramide + sorafenib for 24 h in 2.5% serum medium. After 24 h, cytotoxicity was measured using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega).

Western blot analysis. For Western blot analysis, cell lysates were harvested in Petri dishes by addition of lysis buffer containing 50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10 mmol/L EDTA, 10% glycerol, 1% Triton X-100, 1 mmol/L sodium orthovanadate, 0.1 mmol/L sodium molybdate, 1 mmol/L phenylmethylsulfonyl fluoride, 100 μg/mL soybean trypsin inhibitor, 1 mmol/L benzamidine, and 10 μg/mL leupeptin. Cell lysates were incubated for 30 min on ice, centrifuged at 10,000 rpm for 5 min at 4°C, and an equal volume of 5× SDS sample buffer was added to the supernatant for Western blot analysis. Sample preparation and Western blot analysis were performed as described previously (11).
Sorafenib and Nanoliposomal Ceramide Therapy

fluoride, 20 µg/mL aprotinin, and 5 µg/mL leupeptin. Whole-cell lysates were centrifuged (≥10,000 × g) for 10 min at 4°C to remove cell debris. Protein concentrations were quantitated using the bicinchoninic acid assay from Pierce, and 30 µg of lysate per lane were loaded onto a NuPAGE gel (Life Technologies, Inc.). Following electrophoresis, samples were transferred to polyvinylidene difluoride membrane (Pall Co.). Blots were probed with antibodies according to each supplier’s recommendations: MEK1/2, phosphorylated MEK (pMEK), Akt, and phosphorylated Akt (pAkt) from Cell Signaling Technology; antibodies to B-Raf, ERK2, cyclin D1, and p27 from Santa Cruz Biotechnology. Secondary antibodies were conjugated with horseradish peroxidase and obtained from Santa Cruz Biotechnology. Immunoblots were visualized using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).

Caspase-3/7 detection. Levels of caspase-3/7 activity in cells were measured by plating 5 × 10^5 cells per well in 96-well plates and grown for 48 h in a humidified 37°C cell culture incubator followed by addition of ghost liposome + DMSO vehicle, ghost liposome + sorafenib, nanoliposomal ceramide + DMSO vehicle, or nanoliposomal ceramide + sorafenib in 2.5% serum-containing medium. After 24 h, levels of caspase-3/7 activity were measured using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega). The kit measures caspase-3/7 activity by quantifying cleavage of rhodamine 110, bis-(N-CBZ-L-asparyl-L-glutamyl-L-valyl-L-aspartic acid amide) due to enzymatically active caspase-3/7. Plates were read using a fluorescence plate reader with an excitation of 485 nm and an emission of 530 nm.

Proliferation of cultured cells. To quantify effects of sorafenib and nanoliposomal ceramide on cell proliferation, 5 × 10^5 cells per well were plated in 96-well plates and grown for 48 h in a humidified 37°C cell culture incubator followed by addition of ghost liposome + DMSO vehicle, ghost liposome + sorafenib, nanoliposomal ceramide + DMSO, or nanoliposomal ceramide + sorafenib in medium containing 2.5% serum. After 24 h, bromodeoxyuridine labeling solution from the Cell Proliferation Biotrak ELISA System was added for 16 h, after which samples were processed according to the kit instructions and absorbance was read at 450 nm (Amersham Pharmacia Biotech).

Sorafenib and nanoliposomal ceramide studies in animals. Tumor-inhibitory effect of sorafenib and nanoliposomal ceramide was measured by s.c. injection of 5 × 10^5 UACC 903 cells or 10 × 10^6 MDA-MB-231 cells into nude mice (four mice per group, two tumors per mouse, with two replicates). After 6 d, when a small vascularized tumor (50-100 mm^3) had developed, mice received an i.p. injection on alternate days consisting of 50 µL of vehicle (DMSO), or sorafenib at concentrations of 50 mg/kg body weight for UACC 903 cells and 25 mg/kg body weight for MDA-MB-231 cells (11, 14). Nanoliposomal ceramide or ghost liposomes were delivered i.v. at a dose of 36 mg/kg ceramide. The mechanism by which sorafenib and nanoliposomal ceramide decreased tumorigenicity was identified by s.c. injection of 5 × 10^6 UACC 903 cells followed at day 6 by i.p. injection every 2 d with 50 mg/kg sorafenib and every day injections i.v. of nanoliposomal ceramide. Control groups included DMSO + ghost liposome, sorafenib + ghost liposome, and DMSO + nanoliposomal ceramide at the same dosing schedule. At each time point, tumors of the same size developing in parallel from mice treated with DMSO vehicle or drug were harvested for analysis of cell proliferation, apoptosis, and vascular development (11).

Toxicity analysis. To determine whether the combination of nanoliposomal ceramide and sorafenib was toxic to animals, Swiss Webster mice were injected daily with nanoliposomal ceramide (36 mg/kg) or ghost liposomes and on alternate days with sorafenib (50 mg/kg) or DMSO. The combination of nanoliposomal ceramide and sorafenib was compared with control groups of ghost liposome + DMSO, ghost liposome + sorafenib, and nanoliposomal ceramide + DMSO at the same dosing schedule. Each group of five mice was weighed on alternate days, and after 20 d of treatment, the mice were sacrificed, livers were removed for formalin fixation and paraffin embedding for H&E examination, and blood was collected for analysis to determine changes in serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, glucose, and alkaline phosphatase. Values represent the average of at least four samples ± SE depicted as percentage of ghost liposome + DMSO–treated cells.

Apoptosis, cell proliferation, and vessel density measurements in tumors. Apoptosis measurements on formalin-fixed, paraffin-embedded tumor sections were undertaken using the terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) TMR Red Apoptosis kit from Roche (11, 21). Cell proliferation rates in formalin-fixed tumor sections were measured using Ki-67 staining (33). The number of positive cells per field (1,392 ± 1,040 pixels) was quantified from a minimum of four fields per tumor for both TUNEL and Ki-67 staining. Vessel density was quantified using a purified FITC-conjugated CD31 (platelet endothelial cell adhesion molecule 1) antibody (PharMingen). Frozen sections were fixed in acetone at -20°C for 5 min and rinsed in PBS. Sections were blocked in 1% bovine serum albumin for 30 min after incubation with primary antibody overnight at 4°C. Sections were then rinsed with PBS and mounted using a 4’,6-diamidino-2-phenylindole–containing mountant (Vector Laboratories, Inc.). Proportional area of the tumors occupied by vessels over total area was calculated using the IPLab imaging software program (BD Biosciences Bioimaging). For all tumor analyses, a minimum of three different tumors with four to six fields per tumor was analyzed and results were represented as the average ± SE.

Statistical analysis. One-way or two-way ANOVA followed by the appropriate post hoc test (Tukey’s or Bonferroni) was used to establish whether significant differences existed between groups. Differences were considered significant at P < 0.05. The nature of the interaction between sorafenib and nanoliposomal ceramide was calculated using the Chou-Talalay method for determining the combination index using CalcuSyn software (Biosoft; ref. 34). Based on this approach, combination index values <0.9 are considered synergistic, >1.1 are antagonistic, and values 0.9 to 1.1 are nearly additive (34).

Results

Sorafenib inhibits cancer cell viability. Because sorafenib reduces cancer cell viability by decreasing MAPK pathway signaling, its growth-inhibitory potential was initially confirmed on melanoma and breast cancer cells (11, 14). Melanoma (UACC 903 and 1205 Lu) or breast cancer (MDA-MB-231) cell lines were plated in 96-well plates and treated with increasing concentrations of sorafenib (0.5, 1.0, 1.5, and 2.0 µmol/L) or DMSO vehicle in reduced serum culture medium. Following 24 h of treatment, cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt assay, showing significant reductions in both melanoma and breast cancer cell viability compared with DMSO control–treated cells (Fig. 1A). Similarly, sorafenib inhibited cultured normal human fibroblasts (FF2441), although the agent is well tolerated in patients with manageable toxicity (Fig. 1A; refs. 16, 17, 35).

The effect of sorafenib (0.5, 1.0, 1.5, and 2.0 µmol/L) on MAPK pathway signaling was examined by Western blotting and compared with DMSO vehicle–treated cells. Following 24 and 48 h of sorafenib exposure, pMEK and cyclin D1 levels decreased, whereas p27 protein increased in both breast and melanoma cells (Fig. 1B and C). This pattern is indicative of nonproliferative cells following inhibition of MAPK signaling (2). In contrast, pAkt levels were slightly reduced in UACC 903 cells (Fig. 1B) and were marginally elevated in MDA-MB-231
Sorafenib was originally identified as a Raf kinase inhibitor; however, dependent on the dose and time following treatment, it can affect Akt activity (36). Because no consistent trend was observed in both cell lines in this study and the changes were marginal, effect on Akt activity was considered negligible especially when compared with effects on MAPK signaling. Thus, sorafenib decreased viability of melanoma and breast cancer cells mediated through decreased MAPK cascade activity and had a negligible inconsistent effect on Akt pathway signaling.

**Nanoliposomal ceramide inhibits cell viability.** To validate earlier reports, showing that nanoliposomal ceramide inhibits cell survival mediated through decreased Akt activity, melanoma (UACC 903 and 1205 Lu) and breast cancer (MDA-MB-231) cells were exposed to nanoliposomal ceramide and compared with control human fibroblasts (FF2441) as well as melanocytes (melan-A; refs. 22, 23). Cells were plated in 96-well plates and treated with increasing concentrations of nanoliposomal ceramide (3.125, 6.25, 12.5, and 25 μmol/L) or ghost liposomes lacking ceramide in reduced serum medium, and cell viability was quantified 24 h later. Nanoliposomal ceramide decreased cell viability in UACC 903, 1205 Lu (data not shown), and MDA-MB-231 cells while having minimal effect on fibroblasts (FF2441) and melanocytes (melan-A; data not shown Fig. 2A). Results were consistent with prior reports showing that ceramide had negligible effect on normal breast cells (22).
To examine the effect of nanoliposomal ceramide on PI3K/Akt pathway signaling and validate prior reports that nanoliposomal ceramide decreases Akt activity, UACC 903 or MDA-MB-231 cells were treated with increasing concentrations of nanoliposomal ceramide (12.5, 25.0, and 50.0 μmol/L or 1.5, 3.0, and 6.0 μmol/L, respectively) or ghost liposomes and protein lysates were isolated 24 and 48 h later for Western blot analysis (23). Nanoliposomal ceramide consistently reduced pAkt levels at 24 and 48 h compared with DMSO control–treated cells. In contrast, compared with DMSO–treated cells, pMEK and cyclin D1 remained unchanged or decreased only after 48 h of exposure at the highest concentrations examined when cells were dying due to the inhibitory action of the drug on its target. Thus, results suggested that ceramide had a negligible effect on MAPK signaling (Fig. 2B and C). These results indicate that nanoliposomal ceramide can target cancer cells by inhibiting PI3K/Akt pathway activity.

Sorafenib and nanoliposomal ceramide cooperate to inhibit melanoma and breast cancer cell growth. Because sorafenib and nanoliposomal ceramide are effective inhibitors of melanoma and breast cancer cells, effectiveness of combining agents for...
inhibiting cell survival was evaluated. UACC 903, 1205 Lu, and MDA-MB-231 were treated with sorafenib, nanoliposomal ceramide, or sorafenib plus nanoliposomal ceramide in reduced serum medium and compared with vehicle control (DMSO or ghost liposomes; Fig. 3A). Twenty-four hours later, cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt assay, which showed a pronounced decrease in cell viability for all cell lines with combined agents compared with single treatments (Fig. 3A). Melanoma cells (UACC 903 and 1205 Lu) treated with 1.5 μmol/L sorafenib showed a 27% to 38% reduction in cell viability, whereas cells treated with 12.5 μmol/L nanoliposomal ceramide exhibited a 23% to 41% reduction in viability. In comparison, combined agents decreased cell viability by 65% to 84%, which was an approximately 2- to 4-fold increase compared with single agents (Fig. 3A). Similarly, MDA-MB-231 breast cancer cells treated with 0.25 μmol/L sorafenib or 1.5 μmol/L nanoliposomal ceramide showed a 10% to 13% reduction in cell viability with single agents compared with an ~46% decrease with combined agents, which was an approximately 4- to 5-fold increase in efficacy compared with single agents. Similar inhibitory results of the agent combination were seen with normal human fibroblasts (FF2441; data not shown). Thus, combining sorafenib with nanoliposomal ceramide led to cooperative inhibition of cultured cells.

Fig. 3. Sorafenib and nanoliposomal ceramide cooperate to synergistically decrease viability of cultured cancer cells. A, treatment of melanoma or breast cancer with sorafenib (UACC 903 and 1205 Lu, 1.5 and 2.0 μmol/L; MDA-MB-231, 0.25 and 0.5 μmol/L) and nanoliposomal ceramide (UACC 903 and 1205 Lu, 12.5 and 50 μmol/L; MDA-MB-231, 1.5 and 3.0 μmol/L) in combination cooperates to decrease cell viability compared with single agents, control DMSO, or ghost liposome–treated cells. B and C, combined treatment using sorafenib and nanoliposomal ceramide decreased pAkt, pMEK, and cyclin D1 as well as increased p27 in both melanoma (UACC 903, B) and breast cancer (MDA-MB-231, C) cells. Compared with cells treated for 24 h with control ghost liposomes + DMSO, or monotherapies, sorafenib + nanoliposomal ceramide significantly reduced pAkt and cyclin D1 levels. MEK1/2 served as a control for protein loading.
Sorafenib and nanoliposomal ceramide synergistically decrease cell viability. Because combining sorafenib and nanoliposomal ceramide caused a significant reduction in the proliferative potential of cancer cells, the combination index approach was used to determine whether agents led to additive or synergistic inhibition (34). For melanoma cell lines, combination index values were within ranges of 0.05 to 0.154 for UACC 903 and 0.321 to 0.694 for 1205 Lu, which indicate synergism between sorafenib and nanoliposomal ceramide. MDA-MB-231 results were also consistent with synergism except at 0.5 μmol/L sorafenib and 1.5 μmol/L nanoliposomal ceramide where it was additive, with values between 0.575 and 1.043. Thus, sorafenib and nanoliposomal ceramide cooperate synergistically to decrease melanoma and breast cancer cell survival.

Sorafenib and nanoliposomal ceramide cooperate to decrease PI3K/Akt and MAPK pathway signaling. To ascertain the mechanism leading to synergy between sorafenib and nanoliposomal ceramide, effects on PI3K/Akt and MAPK pathway signaling were examined using Western blot analysis. As predicted, sorafenib decreased pMEK and cyclin D1 levels with corresponding up-regulation of p27, whereas nanoliposomal ceramide decreased pAkt levels for melanoma cells (Fig. 3B). Significantly, combined sorafenib and nanoliposomal ceramide treatment enhanced reduction of pMEK, pAkt, and cyclin D1 levels, with correspondingly increased p27 compared with single-agent treatments (Fig. 3B). A similar trend was observed for breast cancer cells with enhanced reduction of pAkt and cyclin D1 levels (Fig. 3C). However, changes in pMEK1/2 and p27 levels were subtle, likely due to differential pathway signaling. Thus, simultaneous exposure of melanoma or breast cancer cells to sorafenib and nanoliposomal ceramide enhanced down-regulation of PI3K/Akt and MAPK pathway signaling.

Combining sorafenib and nanoliposomal ceramide enhanced apoptosis and cooperatively decreased cell proliferation. Because sorafenib and nanoliposomal ceramide synergistically decreased cancer cell viability, the underlying mechanism contributing to cooperative inhibition was investigated by comparing effects on apoptosis and proliferation. Following 24 h of exposure to sorafenib and/or nanoliposomal ceramide, activity of caspase-3 and caspase-7 was measured. Compared with single agents, combined sorafenib and nanoliposomal ceramide led to a statistically significant 1- to 2-fold increase in cellular apoptosis in both melanoma (Fig. 4A) and breast cancer (Fig. 4B) cells (P < 0.05, one-way ANOVA). Furthermore, TUNEL staining of UACC 903 cells showed a 2-fold increase of apoptosis following combined treatment compared with single agents (data not shown). Next, cellular proliferation was examined by measuring bromodeoxyuridine incorporation (Fig. 4C). Whereas single agents reduced proliferative capacity of UACC 903 melanoma cells by ~2-fold, combined agents decreased proliferation by 3- to 4-fold (P < 0.05, one-way ANOVA; Fig. 4C). Thus, combining sorafenib with nanoliposomal ceramide increased cellular apoptosis and decreased proliferative capacity of
cultured cancer cells, suggesting enhanced efficacy for inhibiting tumor development.

Combining sorafenib and nanoliposomal ceramide enhanced tumor inhibition. Because combining agents was more effective at inhibiting cultured cancer cells, effect on tumor development was examined next. UACC 903 melanoma or MDA-MB-231 breast cancer cells were injected s.c. into nude mice, and after 6 d, mice were treated on alternate days with sorafenib (UACC 903, 50 mg/kg; MDA-MB-231, 25 mg/kg) or DMSO and daily with nanoliposomal ceramide (36 mg/kg) or ghost liposome. Tumors were measured with calipers on alternate days. Significant tumor inhibition occurred when using the combination sorafenib and nanoliposomal ceramide treatment (UACC 903, \( P < 0.05 \), two-way ANOVA). Weights of MDA-MB-231 tumor-bearing mice were measured on alternate days and no significant differences between groups were observed (\( P > 0.05 \), two-way ANOVA). C, weights of Swiss Webster mice treated daily with nanoliposomal ceramide (36 mg/kg) or ghost liposomes and on alternate days with sorafenib (50 mg/kg) or DMSO were measured to establish toxicity. No significant loss of weight was detected (\( P > 0.05 \), two-way ANOVA). D, blood from Swiss Webster mice under the various treatment regimens was collected and analyzed for changes in serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), glucose, and alkaline phosphatase to identify any organ-related toxicity. No significant changes in blood toxicity parameters were seen between groups (\( P > 0.05 \), two-way ANOVA).

Combined sorafenib and nanoliposomal ceramide did not cause systemic toxicity. To further confirm that sorafenib and nanoliposomal ceramide did not induce systemic toxicity compared with control-treated mice, Swiss Webster mice were treated i.v. daily with nanoliposomal ceramide (36 mg/kg) or ghost liposomes and on alternate days i.p. with sorafenib (50 mg/kg) or DMSO. No significant weight loss was observed for any group (\( P > 0.05 \), two-way ANOVA; Fig. 5C). After 20 days of treatment, mice were sacrificed and blood was collected for major organ toxicity assessment. Levels of serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, glucose, and alkaline phosphatase were measured for all groups, and no significant differences were observed between any groups (\( P > 0.05 \), one-way ANOVA; Fig. 5D). In addition, microscopic analysis of H&E-stained liver sections from
experimental and control mice showed no significant morphologic differences (data not shown). Thus, no discernible toxicity was detected in animals treated with nanoliposomal ceramide and sorafenib compared with controls.

**Combining sorafenib with nanoliposomal ceramide enhanced tumor cell apoptosis.** To establish the mechanism leading to tumor inhibition following the combined treatment, size- and time-matched tumors were harvested at days 9 and 11 and compared with single-agent treatments for changes in apoptosis, proliferation, and vascular development. The number of TUNEL-positive apoptotic cells increased significantly for the combined treatment group compared with monotherapies or vehicle-treated control tumors ($P < 0.05$, two-way ANOVA; Fig. 6A). In contrast, no significant changes in proliferation (Fig. 6B) or vascular development (Fig. 6C) compared with single-agent treatments were observed ($P > 0.05$, two-way ANOVA). The sorafenib and nanoliposomal ceramide combination significantly affected cellular apoptosis, which doubled, leading to tumor reduction compared with monotherapies. Thus, combining sorafenib with nanoliposomal ceramide enhanced tumor cell apoptosis, thereby promoting cooperative tumor inhibition.

**Discussion**

Melanoma and breast cancer require more effective treatment options for advanced-stage patients. One possibility involves simultaneously targeting multiple pathways leading to tumorigenesis. Both animal studies and clinical trials show that coadministration of therapeutic agents can be more beneficial than monotherapies (36–40). A case in point is sorafenib where clinical trials show that this agent can be effective in renal cell cancer patients with fewer minor clinically manageable side effects extending life by ~12 weeks (16, 17, 35, 39, 41–44). However, sorafenib is less effective for treating other types of cancer, including melanoma and breast cancer, which is driving the search for agents that can be combined with sorafenib to enhance its clinical efficacy (16, 35, 39, 41, 43, 44).

Combining sorafenib with rottlerin, a protein kinase C inhibitor, which causes synergistic inhibition of cell proliferation and increased apoptosis in glioma cells, shows a solid mechanistic basis for combining these agents in the clinic (36). Furthermore, radiation followed by sorafenib treatment can significantly decrease tumor development in mice by delaying early-phase cell cycle progression (45). Similarly, the present study shows that systemic nanoliposomal ceramide enhances sorafenib efficacy leading to cooperative tumor inhibition, which has therapeutic potential for more effectively treating melanoma and breast cancer.

In the past, the use of ceramide as a therapeutic agent has been limited by cell impermeability, precipitation in aqueous solutions, use of non–Food and Drug Administration-approved excipients, or circulatory metabolism into promitogenic products (22, 23, 29–32). In this study, ceramide was loaded into nanoliposomal delivery vehicles that can be used alone to deliver systemic exogenous ceramide or in conjunction with chemotherapeutics, such as sorafenib (22, 23, 29, 30). These nanoliposomes are 80 ± 15 nm in size and contain 30 mol% cell-permeable ceramide (23). The LD$_{50}$ dose of nanoliposomal ceramide is ~100 mg/kg, which is

![Fig. 6. Sorafenib and nanoliposomal ceramide combination therapy enhances tumor cell apoptosis. Size- and time-matched melanoma (UACC 903) tumors treated with sorafenib + nanoliposomal ceramide were compared with vehicle or single-agent-treated cells at days 9 and 11 ($P < 0.05$, two-way ANOVA). A, statistically significant higher apoptosis levels were observed in tumors treated with nanoliposomal ceramide + sorafenib compared with vehicle- or monotherapy-treated cells at days 9 and 11 ($P < 0.05$, two-way ANOVA). B, decreased proliferation was observed in all groups at days 9 and 11 compared with the control treated tumors ($P < 0.05$, two-way ANOVA). C, no significant differences were observed between individual and combined treatment regimens ($P > 0.05$, two-way ANOVA).](https://www.aacrjournals.org/doi/abs/10.1158/1078-0432.CCR-07-3107)
~4-fold higher than doses used in this study (22). Furthermore, ceramide liposomes selectively kill cancer cells in animal tumors, likely due to accumulation caused by the leaky tumor vasculature (46). Nanoliposomal ceramide mediates apoptosis primarily by inactivation of Akt, which restores cancer cell apoptotic sensitivity, making them receptive to killing via chemotherapeutic agents such as sorafenib (23, 47–49).

Combining sorafenib and nanoliposomal ceramide decreased MAPK and PI3K/Akt signaling, which enhanced apoptosis causing cooperative tumor inhibition. Mechanistically, nanoliposomal ceramide reduced pAkt levels and sensitized cancer cells to apoptosis mediated by sorafenib, thereby effectively killing breast cancer and melanoma cells. Combining sorafenib and nanoliposomal ceramide led to synergistic cooperation between agents in cultured cells and enhanced tumor-inhibitory effectiveness. Furthermore, no significant weight loss, changes in liver morphology, or increases in blood variables indicating systemic toxicity was observed in animals, suggesting negligible systemic toxicity.

Mechanistically, tumor inhibition by combining sorafenib and nanoliposomal ceramide was due to increased apoptosis compared with single agents. Sorafenib has previously been shown to inhibit angiogenesis with decreased proliferation and increased apoptosis being secondary effects (11). In this study, combining sorafenib and nanoliposomal ceramide decreased levels of angiogenesis and proliferation in animal tumors to levels similar to those of the individual agents. In contrast, the combination had a significant effect on tumor cell apoptosis. These results contradict experiments on cultured cells, which showed the combination affected rates of both proliferation and apoptosis. Discrepancies of this type between cell culture and animal studies are common, necessitating pharmacologic agents be tested in animal models and not solely on cultured cells to evaluate efficacy and mechanistic basis for inhibition (50). In conclusion, combining sorafenib with nanoliposomal ceramide has significant therapeutic potential for melanoma and breast cancer patients by significantly increasing cancer cell apoptosis compared with each agent alone.

In conclusion, this study shows that therapeutically targeting the MAPK and PI3K/Akt pathways using sorafenib and nanoliposomal ceramide led to more effective cancer cell inhibition than either single agent alone. The combination synergistically enhanced the antiproliferative actions of sorafenib, which promoted cellular apoptosis in both cultured cells and tumors, with potential to more effectively inhibit melanoma and breast cancer in patients. Thus, this study establishes the foundation for clinical trials evaluating the efficacy of combining sorafenib with nanoliposomal ceramide for treatment of melanoma and breast cancer patients.

Disclosure of Potential Conflicts of Interest

M. Kester: Keystone Nano, Inc. and TRACON Pharmaceuticals. The other authors disclosed no potential conflicts of interest.

Acknowledgments

We thank Dr. Arati Sharma and James Kaiser for technical assistance.

References


Cancer Therapy: Preclinical


Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development

Melissa A. Tran, Charles D. Smith, Mark Kester, et al.

*Clin Cancer Res* 2008;14:3571-3581.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/14/11/3571

Cited articles
This article cites 50 articles, 28 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/14/11/3571.full#ref-list-1

Citing articles
This article has been cited by 15 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/14/11/3571.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.